Ronald P. Mensink
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Ronald P. Mensink has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
Jogchum Plat
From the Department of Human Biology, Maastricht University, Maastricht, Netherlands (RPM, AdJ, and JP); the Institute of Clinical Chemistry and Pharmacology, University of Bonn, Bonn, Germany (DL); and the Department of Pharmacology and Toxicology, Maastricht University, Maastricht, Netherlands (GRMMH)
10 shared publicationsGerard Hornstra
Nutrition and Toxicology Research Institute Maastricht (NUTRIM), Department of Human Biology, Maastricht University, Maastricht, The Netherlands
7 shared publications- Jogchum Plat
Department of Human Biology, Nutrim School for Nutrition, Toxicology and Metabolism Maastricht University Medical Centre P.O. Box 616 Maastricht 6200 MD The Netherlands
5 shared publications Elke Naumann
Department of Human Biology, Maastricht University, PO Box 616, 6200 Maastricht, The Netherlands
3 shared publications- Patrick Schrauwen
Institute for Clinical Diabetology, German Diabetes Center, Leibniz Institute for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany
3 shared publications Dieter Lütjohann
From the Department of Human Biology, Maastricht University, Maastricht, Netherlands (RPM, AdJ, and JP); the Institute of Clinical Chemistry and Pharmacology, University of Bonn, Bonn, Germany (DL); and the Department of Pharmacology and Toxicology, Maastricht University, Maastricht, Netherlands (GRMMH)
2 shared publications
Latest Publications
- 1 February 2013
- Published by Wolters Kluwer Health in Current Opinion in Lipidology
- Vol. 24 (1) , 1-3
Perspective
Nonalcoholic fatty liver disease (NAFLD) has emerged as a clear risk factor for cardiovascular risk. Through its association with metabolic syndrome including insulin resistance and type 2 diabetes, NAFLD certainly has strong indirect associations with cardiovascular risk. Recent population studies have strengthened the association with prevalent coronary heart disease. Investigative cardiology has shown that NAFLD is also associated with markers of subclinical atherosclerosis, such as diminished endothelial function and carotid artery intima-media thickening. Though causality between NAFLD and cardiovascular disease can only be tested in a clinical trial, these recent findings do emphasize the need to develop strategies including nutritional that may prevent NAFLD.
- 1 February 2013
- Published by Wolters Kluwer Health in Current Opinion in Lipidology
- Vol. 24 (1) , 1-3
Perspective
Nonalcoholic fatty liver disease (NAFLD) has emerged as a clear risk factor for cardiovascular risk. Through its association with metabolic syndrome including insulin resistance and type 2 diabetes, NAFLD certainly has strong indirect associations with cardiovascular risk. Recent population studies have strengthened the association with prevalent coronary heart disease. Investigative cardiology has shown that NAFLD is also associated with markers of subclinical atherosclerosis, such as diminished endothelial function and carotid artery intima-media thickening. Though causality between NAFLD and cardiovascular disease can only be tested in a clinical trial, these recent findings do emphasize the need to develop strategies including nutritional that may prevent NAFLD.
- 12 December 2012
- Published by Georg Thieme Verlag KG in Hormone and Metabolic Research
- Vol. 45 (05) , 378-382
Prolonged Fasting and the Effects on Biomarkers of Inflammation and on Adipokines in Healthy Lean Men
Obesity and insulin resistance are associated with low-grade systemic inflammation, which is related to increased concentrations of plasma FFAs, glucose, or insulin. Prolonged fasting induces insulin resistance due to elevated plasma FFAs, but is not accompanied by hyperinsulinemia or hyperglycemia. This makes it possible to study effects of physiologically increased FFA concentrations on inflammatory markers, when insulin and glucose concentrations are not increased. In random order, 10 healthy young lean men (mean BMI: 22.8 kg/m2) were fasted or fed in energy balance for 60 h with a 2-week wash-out period. Subjects stayed in a respiration chamber during the 60-h periods. Blood samples were taken after 12, 36, and 60 h. Then, a hyperinsulinemic-euglycemic clamp was performed. Fasting decreased insulin sensitivity by 45% and increased FFA concentrations 5-fold. Fasting did not change concentrations of the inflammatory cytokines TNF-α, IL-1β, IL-6 and IL-8, or of hs-CRP. Effects on vascular endothelial growth factor (VEGF) – which may positively relate to insulin resistance, and on chemerin and leptin – adipokines related to obesity, and obesity-related pathologies, were also studied. At t=60 h, VEGF concentrations were significantly increased during the fasted period (p<0.05). At the same time point, chemerin (p<0.01) and leptin (p<0.01) were significantly decreased after fasting. For leptin, this decrease was also significant after 36 h (p<0.01). Adiponectin levels remained unchanged. In healthy young lean men, fasting-induced increases in FFAs leading to insulin resistance do not cause changes in concentrations of the inflammatory cytokines. VEGF concentrations increased and those of chemerin decreased.
- 12 December 2012
- Published by Georg Thieme Verlag KG in Hormone and Metabolic Research
- Vol. 45 (05) , 378-382
Prolonged Fasting and the Effects on Biomarkers of Inflammation and on Adipokines in Healthy Lean Men
Obesity and insulin resistance are associated with low-grade systemic inflammation, which is related to increased concentrations of plasma FFAs, glucose, or insulin. Prolonged fasting induces insulin resistance due to elevated plasma FFAs, but is not accompanied by hyperinsulinemia or hyperglycemia. This makes it possible to study effects of physiologically increased FFA concentrations on inflammatory markers, when insulin and glucose concentrations are not increased. In random order, 10 healthy young lean men (mean BMI: 22.8 kg/m2) were fasted or fed in energy balance for 60 h with a 2-week wash-out period. Subjects stayed in a respiration chamber during the 60-h periods. Blood samples were taken after 12, 36, and 60 h. Then, a hyperinsulinemic-euglycemic clamp was performed. Fasting decreased insulin sensitivity by 45% and increased FFA concentrations 5-fold. Fasting did not change concentrations of the inflammatory cytokines TNF-α, IL-1β, IL-6 and IL-8, or of hs-CRP. Effects on vascular endothelial growth factor (VEGF) – which may positively relate to insulin resistance, and on chemerin and leptin – adipokines related to obesity, and obesity-related pathologies, were also studied. At t=60 h, VEGF concentrations were significantly increased during the fasted period (p<0.05). At the same time point, chemerin (p<0.01) and leptin (p<0.01) were significantly decreased after fasting. For leptin, this decrease was also significant after 36 h (p<0.01). Adiponectin levels remained unchanged. In healthy young lean men, fasting-induced increases in FFAs leading to insulin resistance do not cause changes in concentrations of the inflammatory cytokines. VEGF concentrations increased and those of chemerin decreased.
- Open Access
Trans Fatty Acid Intakes and Food Sources in the U.S. Population: NHANES 1999–2002
Because of efforts to decrease trans fatty acids (TFA) in the food supply, intake should be assessed in the population to establish a baseline TFA intake. The 1999–2002 National Health and Nutrition Examination Survey (NHANES) was used to identify a benchmark for TFA intake. TFA was estimated by mean, median, and quintile of intake, TFA intake data were weighted using the NHANES 4‐year sample weights. The main outcome measures included TFA intake in grams per day and percentage of energy in the top 25 food sources of TFA. Data are reported for 16,669 individuals ≥3 years of age. Median TFA intake was 2.3 % of calories (5 g/day) with 0.9–4.5 % of energy (1.5–13.1 g/day) over different quintiles of intake. Mean TFA intake was 2.5 % of energy (6.1 g/day). The range of TFA intake in the fifth quintile was very large, i.e., 3.5–12.5 % of energy or 8.8–92.4 g/day. Increasing quintiles of TFA intake were associated with increases in total fat (26.7–37.6 % of energy), saturated fat (7.6–10.5 % of energy), and calories (for those >20 years of age: 2,416–2,583 for men and 1,679–1,886 for women). Major food sources of dietary TFA were cakes, cookies, pies, and pastries. Based on current dietary guidance to consume as little industrial TFA as possible, much progress is needed to attain this goal, including food industry efforts to remove TFA from the food supply and educating the public about making healthy food choices.
Open AccessTrans Fatty Acid Intakes and Food Sources in the U.S. Population: NHANES 1999–2002
Because of efforts to decrease trans fatty acids (TFA) in the food supply, intake should be assessed in the population to establish a baseline TFA intake. The 1999–2002 National Health and Nutrition Examination Survey (NHANES) was used to identify a benchmark for TFA intake. TFA was estimated by mean, median, and quintile of intake, TFA intake data were weighted using the NHANES 4‐year sample weights. The main outcome measures included TFA intake in grams per day and percentage of energy in the top 25 food sources of TFA. Data are reported for 16,669 individuals ≥3 years of age. Median TFA intake was 2.3 % of calories (5 g/day) with 0.9–4.5 % of energy (1.5–13.1 g/day) over different quintiles of intake. Mean TFA intake was 2.5 % of energy (6.1 g/day). The range of TFA intake in the fifth quintile was very large, i.e., 3.5–12.5 % of energy or 8.8–92.4 g/day. Increasing quintiles of TFA intake were associated with increases in total fat (26.7–37.6 % of energy), saturated fat (7.6–10.5 % of energy), and calories (for those >20 years of age: 2,416–2,583 for men and 1,679–1,886 for women). Major food sources of dietary TFA were cakes, cookies, pies, and pastries. Based on current dietary guidance to consume as little industrial TFA as possible, much progress is needed to attain this goal, including food industry efforts to remove TFA from the food supply and educating the public about making healthy food choices.
- 1 January 2011
- Published by Elsevier in Atherosclerosis
- Vol. 214 (1) , 225-230
Effects of long term plant sterol and -stanol consumption on the retinal vasculature: A randomized controlled trial in statin users
- 1 January 2011
- Published by Elsevier in Atherosclerosis
- Vol. 214 (1) , 225-230
Effects of long term plant sterol and -stanol consumption on the retinal vasculature: A randomized controlled trial in statin users
- Open Access
- 1 July 2010
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 92 (1) , 24-33
Plant stanols dose-dependently decrease LDL-cholesterol concentrations, but not cholesterol-standardized fat-soluble antioxidant concentrations, at intakes up to 9 g/d
Background: It is unclear whether plant stanols lower serum LDL-cholesterol concentrations and cholesterol-standardized fat-soluble antioxidant conce
- 1 July 2010
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 92 (1) , 24-33
Open AccessPlant stanols dose-dependently decrease LDL-cholesterol concentrations, but not cholesterol-standardized fat-soluble antioxidant concentrations, at intakes up to 9 g/d
Background: It is unclear whether plant stanols lower serum LDL-cholesterol concentrations and cholesterol-standardized fat-soluble antioxidant conce
- 31 August 2009
- Published by Springer Nature
- p. 273-284
Cardiovascular Effects of Trans Fatty Acids
- 3 March 2009
- Published by Wiley in Molecular Nutrition & Food Research
- Vol. 53 (3) , 370-376
Consumption of oat β‐glucan with or without plant stanols did not influence inflammatory markers in hypercholesterolemic subjects
We have earlier demonstrated that muesli enriched with oat β‐glucan effectively lowered serum LDL cholesterol. Addition of plant stanols further lowered LDL cholesterol. Besides these hypocholesterolemic effects, β‐glucan and plant stanol esters (PSE) may also affect inflammatory processes. Forty‐two mildly hypercholesterolemic subjects randomly consumed for 4 wk (crossover design) control muesli (4.8 g control fiber), β‐glucan muesli (4.8 g oat β‐glucan), or combination muesli (4.8 g oat β‐glucan plus 1.4 g stanol as PSE). Changes in cytokine production (IL‐6, IL‐8, and TNF‐α) of LPS‐stimulated peripheral blood mononuclear cells (PBMC) and whole blood were evaluated, as well as changes in plasma high‐sensitivity (hs)‐CRP. Additionally, changes in expression profiles of 84 genes involved in atherosclerosis metabolism were assessed in isolated PBMC. IL‐6, IL‐8, and TNF‐α production by PBMC and whole blood after LPS stimulation did not differ between the treatments. Also high‐sensitivity C‐reactive protein (hs‐CRP) levels were similar. β‐Glucan consumption did not change gene expression, while only 3 genes (ADFP, CDH5, CSF2) out of the 84 genes from the atherosclerotic risk panel were differentially expressed (p < 0.05) after consumption of PSE. Consumption of β‐glucan with or without PSE did not influence inflammatory parameters in mildly hypercholesterolemic subjects.
- 3 March 2009
- Published by Wiley in Molecular Nutrition & Food Research
- Vol. 53 (3) , 370-376
Consumption of oat β‐glucan with or without plant stanols did not influence inflammatory markers in hypercholesterolemic subjects
We have earlier demonstrated that muesli enriched with oat β‐glucan effectively lowered serum LDL cholesterol. Addition of plant stanols further lowered LDL cholesterol. Besides these hypocholesterolemic effects, β‐glucan and plant stanol esters (PSE) may also affect inflammatory processes. Forty‐two mildly hypercholesterolemic subjects randomly consumed for 4 wk (crossover design) control muesli (4.8 g control fiber), β‐glucan muesli (4.8 g oat β‐glucan), or combination muesli (4.8 g oat β‐glucan plus 1.4 g stanol as PSE). Changes in cytokine production (IL‐6, IL‐8, and TNF‐α) of LPS‐stimulated peripheral blood mononuclear cells (PBMC) and whole blood were evaluated, as well as changes in plasma high‐sensitivity (hs)‐CRP. Additionally, changes in expression profiles of 84 genes involved in atherosclerosis metabolism were assessed in isolated PBMC. IL‐6, IL‐8, and TNF‐α production by PBMC and whole blood after LPS stimulation did not differ between the treatments. Also high‐sensitivity C‐reactive protein (hs‐CRP) levels were similar. β‐Glucan consumption did not change gene expression, while only 3 genes (ADFP, CDH5, CSF2) out of the 84 genes from the atherosclerotic risk panel were differentially expressed (p < 0.05) after consumption of PSE. Consumption of β‐glucan with or without PSE did not influence inflammatory parameters in mildly hypercholesterolemic subjects.
- Open Access
- 25 February 2009
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 9 (1) , 8
Anti-inflammatory effect of rosiglitazone is not reflected in expression of NFκB-related genes in peripheral blood mononuclear cells of patients with type 2 diabetes mellitus
Background: Rosiglitazone not only improves insulin-sensitivity, but also exerts anti-inflammatory effects. We have now examined in type 2 diabetic patients if these effects are reflected by changes in mRNA expression in peripheral blood mononuclear cells (PBMCs) to see if these cells can be used to study these anti-inflammatory effects at the molecular level in vivo. Method: Eleven obese type 2 diabetic patients received rosiglitazone (2 × 4 mg/d) for 8 weeks. Fasting blood samples were obtained before and after treatment. Ten obese control subjects served as reference group. The expression of NFκB-related genes and PPARγ target genes in PBMCs, plasma TNFα, IL6, MCP1 and hsCRP concentrations were measured. In addition, blood samples were obtained after a hyperinsulinemic-euglycemic clamp. Results: Rosiglitazone reduced plasma MCP1 and hsCRP concentrations in diabetic patients (-9.5 ± 5.3 pg/mL, p = 0.043 and -1.1 ± 0.3 mg/L p = 0.003), respectively). For hsCRP, the concentration became comparable with the non-diabetic reference group. However, of the 84 NFκB-related genes that were measured in PBMCs from type 2 diabetic subjects, only RELA, SLC20A1, INFγ and IL1R1 changed significantly (p < 0.05). In addition, PPARγ and its target genes (CD36 and LPL) did not change. During the clamp, insulin reduced plasma MCP1 concentration in the diabetic and reference groups (-9.1 ± 1.8%, p = 0.001 and -11.1 ± 4.1%, p = 0.023, respectively) and increased IL6 concentration in the reference group only (23.5 ± 9.0%, p = 0.028). Conclusion: In type 2 diabetic patients, the anti-inflammatory effect of rosiglitazone is not reflected by changes in NFκB and PPARγ target genes in PBMCs in vivo. Furthermore, our results do not support that high insulin concentrations contribute to the pro-inflammatory profile in type 2 diabetic patients.
- 25 February 2009
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 9 (1) , 8
Open AccessAnti-inflammatory effect of rosiglitazone is not reflected in expression of NFκB-related genes in peripheral blood mononuclear cells of patients with type 2 diabetes mellitus
Background: Rosiglitazone not only improves insulin-sensitivity, but also exerts anti-inflammatory effects. We have now examined in type 2 diabetic patients if these effects are reflected by changes in mRNA expression in peripheral blood mononuclear cells (PBMCs) to see if these cells can be used to study these anti-inflammatory effects at the molecular level in vivo. Method: Eleven obese type 2 diabetic patients received rosiglitazone (2 × 4 mg/d) for 8 weeks. Fasting blood samples were obtained before and after treatment. Ten obese control subjects served as reference group. The expression of NFκB-related genes and PPARγ target genes in PBMCs, plasma TNFα, IL6, MCP1 and hsCRP concentrations were measured. In addition, blood samples were obtained after a hyperinsulinemic-euglycemic clamp. Results: Rosiglitazone reduced plasma MCP1 and hsCRP concentrations in diabetic patients (-9.5 ± 5.3 pg/mL, p = 0.043 and -1.1 ± 0.3 mg/L p = 0.003), respectively). For hsCRP, the concentration became comparable with the non-diabetic reference group. However, of the 84 NFκB-related genes that were measured in PBMCs from type 2 diabetic subjects, only RELA, SLC20A1, INFγ and IL1R1 changed significantly (p < 0.05). In addition, PPARγ and its target genes (CD36 and LPL) did not change. During the clamp, insulin reduced plasma MCP1 concentration in the diabetic and reference groups (-9.1 ± 1.8%, p = 0.001 and -11.1 ± 4.1%, p = 0.023, respectively) and increased IL6 concentration in the reference group only (23.5 ± 9.0%, p = 0.028). Conclusion: In type 2 diabetic patients, the anti-inflammatory effect of rosiglitazone is not reflected by changes in NFκB and PPARγ target genes in PBMCs in vivo. Furthermore, our results do not support that high insulin concentrations contribute to the pro-inflammatory profile in type 2 diabetic patients.
- 1 February 2009
- Published by Wolters Kluwer Health in Current Opinion in Lipidology
- Vol. 20 (1) , 1-2
Trans fatty acids and cardiovascular risk markers: does the source matter?
- 1 February 2009
- Published by Wolters Kluwer Health in Current Opinion in Lipidology
- Vol. 20 (1) , 1-2
Trans fatty acids and cardiovascular risk markers: does the source matter?